复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02696 复宏汉霖

已收盘 04-09 16:08:13

80.000

+0.750

+0.95%

最高80.450	最低77.300	成交量110.10万
今开79.600	昨收79.250	日振幅3.97%
总市值434.40亿	流通市值276.86亿	总股本5.43亿
成交额8,745万	换手率0.32%	流通股本3.46亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02696","market":"HK","secType":"STK","nameCN":"复宏汉霖","latestPrice":80,"timestamp":1775722093006,"preClose":79.25,"halted":0,"volume":1101018,"delay":0,"changeRate":0.00946372239747634,"floatShares":346074397,"shares":543000000,"eps":1.7294559808058412,"marketStatus":"已收盘","change":0.75,"latestTime":"04-09 16:08:13","open":79.6,"high":80.45,"low":77.3,"amount":87445343,"amplitude":0.039748,"askPrice":80,"askSize":9000,"bidPrice":79.6,"bidSize":200,"shortable":3,"etf":0,"ttmEps":1.7298936095203026,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1775784600000},"marketStatusCode":5,"adr":0,"listingDate":1569340800000,"exchange":"SEHK","adjPreClose":79.25,"openAndCloseTimeList":[[1775698200000,1775707200000],[1775710800000,1775721600000]],"volumeRatio":0.435673,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02696","defaultTab":"news","newsList":[{"id":"1138335897","title":"复宏汉霖更新3月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1138335897","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138335897?lang=zh_cn&edition=full","pubTime":"2026-04-08 18:26","pubTimestamp":1775643965,"startTime":"0","endTime":"0","summary":"复宏汉霖于2026年4月8日公布了截至2026年3月31日的股份变动月报。报告显示，公司本月无新增发行或回购活动，整体已发行股本维持不变。根据公告，截至3月末，公司注册股本总额为543,494,853元人民币，其中已上市H股346,074,397股，非上市股份197,420,456股，上述数值与上月底持平。公司确认继续符合香港联交所相关公众持股量要求。截至报告期末，7,009,500份受限制股份单位仍在有效期内。本次月报由公司董事Wenjie ZHANG签署并向香港联交所提交。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624509771","title":"对话复宏汉霖CEO朱俊：海外收入占比3%只是开始，将在欧美市场挖掘新增量","url":"https://stock-news.laohu8.com/highlight/detail?id=2624509771","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624509771?lang=zh_cn&edition=full","pubTime":"2026-04-02 20:24","pubTimestamp":1775132686,"startTime":"0","endTime":"0","summary":"\"\"近日，复宏汉霖发布了2025年年报，公司实现营业收入66.67亿元，同比增长16.5%；实现归母净利润8.27亿元，同比增长0.80%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604023693676396.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604023693676396.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","HK0000320223.HKD","HK0000306701.USD","HK0000306685.HKD","HK0000165453.HKD","HK0000320264.USD","02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624359620","title":"复宏汉霖(02696)：帕妥珠曲妥珠单抗注射液(皮下注射)生物类似药HLX319的1期临床试验申请获国家药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2624359620","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624359620?lang=zh_cn&edition=full","pubTime":"2026-04-01 17:04","pubTimestamp":1775034245,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，公司自主研发的帕妥珠曲妥珠单抗注射液生物类似药HLX319的1期临床试验申请获国家药品监督管理局批准。HLX319是公司自主研发的帕妥珠曲妥珠单抗注射液生物类似药，由活性成分曲妥珠单抗、帕妥珠单抗和辅料玻璃酸酶组成，拟用于早期乳腺癌的辅助/新辅助治疗与转移性乳腺癌的治疗。根据IQVIA MIDASTM的资料，2025年度，帕妥珠曲妥珠单抗注射液于全球的销售额约为30.23亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423984.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02696","HK0000320223.HKD","HK0000306685.HKD","HK0000306701.USD","HK0000165453.HKD","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624456542","title":"港股异动 | 复宏汉霖(02696)涨超6% 自研HLXTEHAase02的1期临床试验申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2624456542","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624456542?lang=zh_cn&edition=full","pubTime":"2026-04-01 11:21","pubTimestamp":1775013673,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖涨超6%，截至发稿，涨5.38%，报73.5港元，成交额8899.7万港元。消息面上，3月31日，复宏汉霖发布公告，近日，公司自主研发的HLXTEHAase02的1期临床试验申请获国家药品监督管理局批准。HLXTE-HAase02拟用于皮下给药产品的开发，帮助这些药物实现更有效的皮下递送。非临床研究显示，HLXTE-HAase02展现出与已上市重组人透明质酸产品相当的酶活性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423789.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306685.HKD","BK4588","VXUS","BK4585","HK0000320223.HKD","HK0000165453.HKD","HK0000320264.USD","HK0000306701.USD","BK1161","02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184585813","title":"复宏汉霖HLXTE-HAASE02一期临床试验IND申请获中国药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1184585813","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184585813?lang=zh_cn&edition=full","pubTime":"2026-03-31 18:02","pubTimestamp":1774951330,"startTime":"0","endTime":"0","summary":"复宏汉霖（HENLIUS）宣布，其创新药HLXTE-HAASE02的一期临床试验新药研究申请（IND）已获得中国国家药品监督管理局（NMPA）的正式批准。此次获批标志着该药物正式进入临床开发阶段，为公司肿瘤治疗领域的产品管线增添了新的重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000320223.HKD","BK1161","HK0000306685.HKD","HK0000320264.USD","02696","HK0000306701.USD","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623003803","title":"复宏汉霖(02696)自主研发的HLXTEHAase02的1期临床试验申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2623003803","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623003803?lang=zh_cn&edition=full","pubTime":"2026-03-31 18:00","pubTimestamp":1774951218,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 公布，近日，公司自主研发的HLXTEHAase02的1期临床试验申请获国家药品监督管理局批准。HLXTE-HAase02在生理条件下可局部且可逆地特异性解聚皮下组织透明质酸，增大皮下给药体积，增强药物在皮下组织内的分散度和渗透性，进而增加药物的生物利用度，提高患者皮下给药的依从性。HLXTE-HAase02拟用于皮下给药产品的开发，帮助这些药物实现更有效的皮下递送。非临床研究显示，HLXTE-HAase02展现出与已上市重组人透明质酸产品相当的酶活性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423038.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"复宏汉霖(02696)自主研发的HLXTEHAase02的1期临床试验申请获批","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306701.USD","BK1161","HK0000306685.HKD","HK0000320264.USD","02696","HK0000320223.HKD","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623315758","title":"复宏汉霖(02696)：斯鲁利单抗注射液获欧洲药品管理局人用医药产品委员会积极审评意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2623315758","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623315758?lang=zh_cn&edition=full","pubTime":"2026-03-30 17:58","pubTimestamp":1774864728,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，公司自主开发的斯鲁利单抗注射液(汉斯状) 获欧洲药品管理局人用医药产品委员会积极审评意见。CHMP的审评意见将会被递交至欧盟委员会， EC将参考该意见并在未来2个月内做出最终审查决定。一旦获得EC 批准，汉斯状的集中上市许可将在所有欧盟成员国及欧洲经济区国家冰岛、列支敦士登和挪威生效。此次CHMP的积极意见主要是基于两项随机、双盲、多中心3期临床研究。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421838.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","HK0000165453.HKD","HK0000306701.USD","BK1515","09939","159938","02696","HK0000306685.HKD","HK0000320264.USD","HK0000320223.HKD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622819299","title":"复宏汉霖盘中涨近7% 招银国际维持其“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2622819299","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622819299?lang=zh_cn&edition=full","pubTime":"2026-03-27 11:07","pubTimestamp":1774580867,"startTime":"0","endTime":"0","summary":"复宏汉霖盘中涨近7%，截至发稿，股价上涨5.83%，现报69.85港元，成交额2056.855万港元。此外，近日，复宏汉霖地舒单抗BILDYOS与TUZEMTY获加拿大卫生部上市批准。值得注意的是，复宏汉霖2025年收入同比增长16.5%，达到66.7亿元，归属于股东净利润8.27亿元。招银国际发布研报称，复宏汉霖受惠于稳健的产品销售增长，2025财年业绩强劲。维持对其“买入”评级，目标价由97.75港元微升至99.78港元。","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/03/27110756492011.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124115143","title":"异动解读 | 复宏汉霖盘中大涨6.36%，研发进展及海外获批提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1124115143","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124115143?lang=zh_cn&edition=full","pubTime":"2026-03-27 10:26","pubTimestamp":1774578418,"startTime":"0","endTime":"0","summary":"复宏汉霖今日盘中股价大涨6.36%，引起了市场的广泛关注。消息面上，公司近期在研发和商业化方面取得积极进展。其HLX701联合疗法治疗晚期结直肠癌的1b/2期临床研究已完成首例患者给药。同时，公司旗下产品地舒单抗BILDYOS与TUZEMTY获得了加拿大卫生部的上市批准，标志着其海外市场拓展取得新突破。此外，公司2025年业绩表现强劲，收入同比增长16.5%至66.7亿元人民币，归属于股东净利润达8.27亿元。核心产品汉曲优和汉斯状销售持续放量，全球收入分别达到29.9亿元和15.0亿元。海外业务增长尤为亮眼，产品收入超过2亿元，同比增幅超过100%，展现了强劲的增长潜力。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622816137","title":"港股异动 | 复宏汉霖(02696)早盘涨近7% 核心产品放量及海外收入高增增 全年产品收入超58亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622816137","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622816137?lang=zh_cn&edition=full","pubTime":"2026-03-27 10:18","pubTimestamp":1774577903,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖早盘涨近7%，截至发稿，涨6.21%，报70.1港元，成交额1216.71万港元。此外，近日，复宏汉霖地舒单抗BILDYOS与TUZEMTY获加拿大卫生部上市批准。值得注意的是，复宏汉霖2025年收入同比增长16.5%，达到66.7亿元，归属于股东净利润8.27亿元。申万宏源发布研报称，受益于核心产品销售放量，例如汉曲优和汉斯状，以及海外收入快速增长，2025年公司全球产品总收入达到58.2亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420213.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000320264.USD","02696","BK4588","BK4585","HK0000306685.HKD","BK1161","HK0000165453.HKD","HK0000306701.USD","HK0000320223.HKD","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622309408","title":"复宏汉霖(02696)：HLX701联合西妥昔单抗和化疗治疗晚期结直肠癌的1b/2期临床研究于中国境内完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2622309408","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622309408?lang=zh_cn&edition=full","pubTime":"2026-03-26 16:54","pubTimestamp":1774515286,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，HLX701联合西妥昔单抗和化疗治疗晚期结直肠癌的1b/2期临床研究于中国境内完成首例患者给药。HLX701是本公司自FBD Biologics Limited许可引进的SIRPα-Fc融合蛋白，拟用于多种晚期实体瘤的治疗，目前该产品的多项1/2期临床试验正于全球范围内开展中。2026年1月，HLX701联合西妥昔单抗和化疗治疗晚期结直肠癌的1b/2期临床试验申请获国家药品监督管理局批准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419489.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02696","HK0000320264.USD","HK0000306701.USD","HK0000306685.HKD","HK0000165453.HKD","BK1161","HK0000320223.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622704233","title":"【天风医药杨松团队|公司点评】复宏汉霖：业绩超预期，看好后续业绩管线双丰收","url":"https://stock-news.laohu8.com/highlight/detail?id=2622704233","media":"市场资讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622704233?lang=zh_cn&edition=full","pubTime":"2026-03-25 13:47","pubTimestamp":1774417620,"startTime":"0","endTime":"0","summary":"公司业绩持续增长，体现出公司在乳腺癌及肺癌领域卓越的商业化能力，且未来有望通过重磅新品的上市，打造未来战略核心。核心在于公司PD-1在一线小细胞肺癌、围手术期胃癌及一线转移性结直肠癌的3个重磅适应症。公司PD1有望成为首个用于一线转移性结直肠癌的PD-1联合VEGF疗法，预计 2027 年公布MRCT临床结果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-03-25/doc-inhseqhc9842225.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","BK1574","HK0000320264.USD","02696","HK0000306701.USD","09939","HK0000306685.HKD","159938","BK1161","HK0000320223.HKD","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622043016","title":"招银国际：维持复宏汉霖(02696)“买入”评级 目标价微升至99.78港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622043016","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622043016?lang=zh_cn&edition=full","pubTime":"2026-03-25 10:46","pubTimestamp":1774406806,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招银国际发布研报称，复宏汉霖(02696)受惠于稳健的产品销售增长，2025财年业绩强劲。该公司正扩大其全球生物类似药的市场版图，并建立新的国际合作伙伴关系。维持对其“买入”评级，目标价由97.75港元微升至99.78港元。报告指，公司正加速转型为具创新力的生物制剂龙头企业，其发展由HLX43、HLX22及serplulimab等具竞争力的产品领衔。预期2026年将出现多项临床及监管层面的催化因素。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418525.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172014153","title":"异动解读 | 招银国际维持买入评级并上调目标价，复宏汉霖盘中大涨5.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=1172014153","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172014153?lang=zh_cn&edition=full","pubTime":"2026-03-25 10:24","pubTimestamp":1774405490,"startTime":"0","endTime":"0","summary":"复宏汉霖今日盘中股价大幅上涨5.23%，引起了市场关注。消息面上，招银国际发布研究报告，维持对复宏汉霖的“买入”评级，并将其目标价由97.75元微升至99.78元。报告指出，公司受益于稳健的产品销售增长，2025财年业绩表现强劲。同时，公司正积极扩大其全球生物类似药的市场版图，并建立新的国际合作伙伴关系，加速向创新生物制剂龙头企业转型。其产品线中HLX43、HLX22及serplulimab等具有竞争力的产品发展领先，预期2026年将出现多项临床及监管层面的积极催化因素。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621834777","title":"复宏汉霖(2696.HK)逆势收涨2.34% 绩后获高盛上调盈测及目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=2621834777","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621834777?lang=zh_cn&edition=full","pubTime":"2026-03-23 18:37","pubTimestamp":1774262221,"startTime":"0","endTime":"0","summary":"板块中仅少数股票逆势上涨，其中，复宏汉霖逆势收涨2.34%，报65.65港元，市值356.8亿港元。　　消息面上，复宏汉霖上周五发布2025年年度业绩。　　高盛最新发研报指，复宏汉霖去年下半年总收入按年升29%至38亿元，其中中国内地销售胜于预期，按年升31%至32亿元。该行将复宏汉霖今年及明年销售预测分别上调8.6%及8.3%，维持2028年销售预测不变，各年纯利预测则分别上调3,800万元、2.24亿元及1.43亿元，将其目标价由102.72港元上调至104.79港元，评级“买入”。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260323/32090766.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621677593","title":"高盛：给予复宏汉霖(02696)“买入”评级 上调目标价至104.79港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621677593","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621677593?lang=zh_cn&edition=full","pubTime":"2026-03-23 16:00","pubTimestamp":1774252858,"startTime":"0","endTime":"0","summary":"复宏汉霖去年下半年总收入同比升29%至38亿元人民币，其中中国内地销售胜于预期，同比升31%至32亿元人民币","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260323/20260323160225_21395.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260323/20260323160225_21395.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417314.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621772175","title":"营收66.666亿，净利8.3亿，深挖复宏汉霖(02696)2025年报背后的投资确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=2621772175","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621772175?lang=zh_cn&edition=full","pubTime":"2026-03-23 13:10","pubTimestamp":1774242619,"startTime":"0","endTime":"0","summary":"连续三年营收利润双增，筑牢创新与国际化根基财报显示，公司报告期内实现营收66.666亿元，同比增长16.5%;净利润8.27亿元。自2023年首次实现全年盈利以来，连续三年实现营收、利润双增长，是此次复宏汉霖年报展现的最直观的亮点。汉奈佳当期实现销售收入3.01亿元，同比大幅增长564.2%，持续巩固其在HER2阳性早期乳腺癌强化辅助治疗中的优势品牌地位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417240.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621109687","title":"复宏汉霖：2025年实现营收66.666亿元 净利润8.270亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621109687","media":"证券日报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621109687?lang=zh_cn&edition=full","pubTime":"2026-03-22 21:35","pubTimestamp":1774186500,"startTime":"0","endTime":"0","summary":"3月20日，上海复宏汉霖生物技术股份有限公司（以下简称“复宏汉霖”）发布2025年年度业绩。业绩期内，该公司实现营收66.666亿元，同比增长16.5%；净利润8.270亿元，同比增长0.80%；经营性现金流净流入13.1亿元。2025年，复宏汉霖全球化增长动能持续释放，全球产品收入达到57.746亿元，同比增长17.0%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603223679787232.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620978209","title":"复宏汉霖(02696)发布年度业绩，收入66.67亿元 同比增长16.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620978209","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620978209?lang=zh_cn&edition=full","pubTime":"2026-03-20 18:20","pubTimestamp":1774002043,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布截至2025年12月31日止年度业绩，该集团取得收入66.67亿元，同比增加16.46%;母公司拥有人应占利润8.27亿元，同比增加0.8%;每股基本盈利1.52元。截至2025年12月31日止年度，本集团确认研发开支约24.92亿元，较2024年12月31日止年度约18.405亿元增加约6.51亿元，主要用于加大对创新型研发项目的投入以加速本集团创新转型。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416653.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"复宏汉霖(02696)发布年度业绩，收入66.67亿元 同比增长16.46%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306685.HKD","HK0000165453.HKD","02696","BK1161","HK0000306701.USD","HK0000320264.USD","HK0000320223.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620782400","title":"复宏汉霖(02696)：纳武利尤单抗生物类似药HLX18(重组抗PD-1人源化单克隆抗体注射液)用于多种实体瘤治疗的1期临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2620782400","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620782400?lang=zh_cn&edition=full","pubTime":"2026-03-20 18:14","pubTimestamp":1774001646,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，本公司自主研发的纳武利尤单抗生物类似药HLX18用于多种实体瘤治疗的1期临床试验申请获国家药品监督管理局批准。部分肿瘤细胞的PD-1配体上调，通过这个通路信号传导可抑制激活的T细胞对肿瘤的免疫监视。2025年12月， HLX18于美国获许可开展用于多种实体瘤治疗的1期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416649.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PD","HK0000306701.USD","HK0000320223.HKD","BK4023","BK1161","HK0000165453.HKD","LU1169590202.USD","02696","LU1169589451.USD","HK0000306685.HKD","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0441},{"period":"1month","weight":0.2017},{"period":"3month","weight":0.198},{"period":"6month","weight":0.1068},{"period":"1year","weight":2.0364},{"period":"ytd","weight":0.3891}],"compareEarnings":[{"period":"1week","weight":0.0237},{"period":"1month","weight":0.0191},{"period":"3month","weight":-0.0098},{"period":"6month","weight":-0.0151},{"period":"1year","weight":0.2864},{"period":"ytd","weight":0.0102}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复宏汉霖生物技术股份有限公司是一家主要从事生物制药研发、生物制药服务及生物制药生产与销售的中国公司。该公司的主要产品包括汉曲优（注射用曲妥珠单抗）、汉奈佳（马来酸奈拉替尼片）、汉斯状（斯鲁利单抗注射液）、汉利康（利妥昔单抗注射液）、汉达远（阿达木单抗注射液）、汉贝泰（贝伐珠单抗注射液）等。该公司的产品主要应用于乳腺癌辅助治疗、转移性乳腺癌及转移性胃癌治疗、转移性非鳞状非小细胞肺癌、多关节型幼年特发性关节炎治疗等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.044394},{"month":2,"riseRate":0.714286,"avgChangeRate":0.117695},{"month":3,"riseRate":0.571429,"avgChangeRate":-0.008815},{"month":4,"riseRate":0.857143,"avgChangeRate":0.129675},{"month":5,"riseRate":0.5,"avgChangeRate":-0.024483},{"month":6,"riseRate":0.666667,"avgChangeRate":0.109389},{"month":7,"riseRate":0.5,"avgChangeRate":0.069459},{"month":8,"riseRate":0.5,"avgChangeRate":-0.024213},{"month":9,"riseRate":0,"avgChangeRate":-0.127435},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.025526},{"month":11,"riseRate":0.571429,"avgChangeRate":0.058675},{"month":12,"riseRate":0.714286,"avgChangeRate":-0.023816}],"exchange":"SEHK","name":"复宏汉霖","nameEN":"HENLIUS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复宏汉霖,02696,复宏汉霖股票,复宏汉霖股票老虎,复宏汉霖股票老虎国际,复宏汉霖行情,复宏汉霖股票行情,复宏汉霖股价,复宏汉霖股市,复宏汉霖股票价格,复宏汉霖股票交易,复宏汉霖股票购买,复宏汉霖股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}